Amid the AI boom, a quieter revolution is unfolding at the intersection of photons, silicon, and stethoscopes—and investors are starting to lean in.
From Qubits to Check‑Ups: Two Infrastructure Bets Hiding in Plain Sight
If Silicon Valley once ran on sand and software, the next decade may run on qubits and virtual care workflows. On one side of the Bay, PsiQuantum is attempting the technological equivalent of tightrope walking across the Grand Canyon in a headwind: building a one‑million‑qubit, fault‑tolerant quantum computer using standard semiconductor manufacturing and photonics. The company has raised more than 2 billion dollars, sports a valuation north of 7 billion dollars, and counts NVIDIA Corporation (NASDAQ: NVDA) and BlackRock, Inc. (NYSE: BLK) among the investors willing to fund that high‑wire act. On the other side of the country, American Well Corporation, doing business as Amwell (NYSE: AMWL), is pursuing a more prosaic mission that may prove just as consequential for returns: becoming the digital operating system for hybrid healthcare by connecting providers, payers, patients, and innovators through a single virtual care platform and hardware ecosystem.
One is building the machine that could one day redesign molecules; the other is wiring the messy, reimbursed, regulated reality of how care is actually delivered. Both share a common thread that tends to age well on Wall Street: if they work, they become foundational.
PsiQuantum: When “Exponential Money” Meets Industrial Pragmatism
PsiQuantum’s Milpitas facility is housed in what was once the last production chip fab in Silicon Valley, repurposed into a quantum factory that looks less like a lab experiment and more like a specialized data center with a cryogenic addiction. Co‑founder and Chief Scientific Officer Pete Shadbolt describes the company’s philosophy with the kind of deadpan that typically precedes large capital calls: “From the very beginning, we’ve just been pigheadedly interested in building million‑qubit‑scale machines.” Rather than chasing elegant lab demos, the team is designing around pre‑existing, high‑volume semiconductor and photonics supply chains—standard fabs, fibers, and off‑the‑shelf cooling infrastructure—while reserving the real innovation for the quantum stack itself. The core building block is a photonic module: a cluster of chips etched to guide light instead of electrons, creating qubits by sending single photons through waveguides and beam splitters, and reading them out with superconducting single‑photon detectors that can spot individual particles of light with roughly 99% efficiency. Roughly one hundred such modules, each carrying hundreds of chips, forms the skeleton of a million‑qubit machine, cooled by a massive helium‑based cryoplant—itself described as “basically the form factor” of the eventual system.
The investment case—and the risk—is temporal. There are, as Shadbolt notes with uncomfortable candor, “no useful quantum computers on the planet” today; existing systems are research tools with no commercial must‑have application. Yet consensus across much of the industry has converged around the end of this decade as the plausible window for the first fault‑tolerant, utility‑scale machines.
If that timeline holds, the payoff is not incremental productivity; it is category creation. At scale, quantum computers could radically reshape how we approach high‑value problems in chemistry, materials science, and finance—moving from today’s non‑deterministic, trial‑and‑error discovery processes toward more deterministic design of drugs, catalysts, fuels, and complex financial structures.
Shadbolt’s favored phrase is “a categorically new level of mastery over chemistry, physics, and math”—a line that reads like hype until you recall that every prior leap in compute has minted a new class of dominant platforms, from mainframes to cloud to AI accelerators. Whether PsiQuantum ultimately captures that value or merely proves the path for others is, for investors, the multi‑billion‑dollar question. For now, the presence of NVIDIA and BlackRock on the cap table signals that the “smart money” is at least willing to pay for a front‑row seat.
Amwell: The Quiet Plumbing of Hybrid Care
If PsiQuantum is chasing the future of physics, Amwell is focused on the far less glamorous, but immediately billable, business of making healthcare delivery work in a world where “in‑person” and “virtual” are no longer competing adjectives but adjacent tabs in the same clinical workflow.
Amwell positions itself not as a direct‑to‑consumer telehealth brand but as an enterprise platform that digitally empowers health systems, health plans, employers, and innovators to deliver care across the continuum—urgent, acute, post‑acute, behavioral, chronic, and even healthy living. Its Converge platform and Carepoint hardware effectively act as the connective tissue between physical facilities and digital touchpoints, allowing hospitals to transform telehealth from “video visits bolted onto the side” into an integrated, hybrid model of care. The scale is already non‑trivial. Amwell supports roughly 90 million members who have access to its services as a covered benefit, works with about 80 U.S. health systems, and has facilitated approximately 37.6 million virtual visits since inception. The company’s enterprise platform powers provider‑to‑provider virtual care for scenarios such as telestroke, virtual nursing, and e‑sitting, while its Carepoint carts, TV kits, and tablet‑based devices turn bedsides and clinical stations into digital access points.
From an investor’s perspective, this looks less like a pure “telehealth app” and more like a specialized software‑and‑devices infrastructure layer where switching costs reside not in a smartphone icon but in deeply embedded workflows, integrations, credentialing, and compliance. The company’s ESG and security posture—highlighting data privacy, information security certifications, and enterprise risk management—speaks directly to the procurement checklists of large health systems and payers. In other words, Amwell is trying to become the boring, indispensable middleware of modern care delivery. Wall Street has historically done well with boring and indispensable, once it learns to look past early‑stage losses and regulatory noise.
Why These Bets Rhymes With Prior Platform Shifts
Investors trying to map these stories onto familiar terrain could do worse than thinking in terms of “platform leverage.”
- Quantum computing, if realized at scale, is not a feature; it is a new substrate for entire industries, especially those constrained by computational intractability—drug discovery, molecular modeling, optimization, and certain classes of financial modeling. In that world, equity in the earliest successful platform providers is functionally an option on a new compute regime..
- Enterprise digital care platforms such as Amwell’s Converge are not point solutions; they are operating layers where many future services—from AI triage and automated chronic‑care programs to behavioral health modules—will eventually plug in. Equity here is an option on the normalization of hybrid care as a default model and the subsequent monetization of that traffic..
Thematically, both PsiQuantum and Amwell are infrastructure stories: one at the level of fundamental physics, the other at the level of regulated workflows. Both are also, in their own ways, anti‑fashion. PsiQuantum’s strategy is to avoid reinvention in everything that can be purchased off the shelf—from cryogenic pumps to photonic manufacturing—while saving its risk budget for the quantum stack. Amwell’s approach is to quietly re‑platform the unglamorous middle of healthcare delivery, far from the headline‑grabbing consumer apps.
For investors accustomed to AI narratives where each foundation model appears to demand “exponential money for linear progress,” there is a certain grim humor in Shadbolt’s gratitude that quantum does not share that particular pathology—at least not in the same way. Building a million‑qubit machine is still brutally hard, but the cost curve is tied more to industrial scaling than to endlessly retraining larger models on internet exhaust..
Positioning Around an Asymmetric Future
None of this absolves investors from the uncomfortable part: timing. Quantum remains pre‑revenue in any meaningful sense; telehealth remains exposed to policy, reimbursement, and macro cycles.
Yet the asymmetry is hard to ignore. If PsiQuantum or its peers deliver a fault‑tolerant photonic machine by decade’s end, the upside will likely accrue first to those who underwrote the long, unfashionable phase of hardware and fabrication risk. If Amwell succeeds in becoming the de facto orchestration layer for large swaths of hybrid care, its installed base of members, health systems, and devices becomes a distribution channel for future services in behavioral health, chronic disease management, and AI‑enabled “automated care” programs. In a market captivated by short‑term AI winners, there is room in a sophisticated portfolio for what might be called “patient infrastructure” bets—assets where the payoff profile looks less like a quarterly beat and more like optionality on the next epoch of compute and care. NVIDIA and BlackRock have already placed their chips on PsiQuantum, effectively signaling that quantum is graduating from whiteboard speculation to institutional diligence. Amwell, trading as AMWL on the New York Stock Exchange, is further along the commercialization curve, with real customers, real utilization metrics, and the very real headaches of operating in healthcare.
For investors willing to think beyond the current AI cycle, these two stories offer a simple, if slightly mischievous, framing: one is building the computer that may one day design the molecule that your doctor prescribes; the other is building the platform through which that doctor will actually deliver the visit. As always, the market will decide how to price that connective tissue. The question for portfolio constructors is whether they want to be long or merely entertained when it does.
Learn More From PsiQuantum
The Sources
- PsiQuantum – “Why NVIDIA & BlackRock Are Betting $2.3B on This Startup” (YouTube video)
https://www.youtube.com/watch?v=2jshwfW6b4Q - Amwell – About Us (company site)
https://business.amwell.com/about-us - Amwell – Overview Brochure (platform, devices, hybrid care details)
https://cdn.prod.website-files.com/5bf603f84ae3426101807d56/609ae72c6a448737227ebfdb_Amwell%20Overview%20Brochure.pdf - American Well Corporation (Amwell) – Company profile & facts (Yahoo Finance, AMWL)
https://ca.finance.yahoo.com/quote/AMWL/profile/ - American Well Corp (AMWL) – Company information (HL)
https://www.hl.co.uk/shares/shares-search-results/a/american-well-corp-usd0.01-a/company-information - Amwell – Company overview and description (GlobalData)
https://www.globaldata.com/company-profile/american-well-corp/ - Amwell – Leadership team and company positioning
https://business.amwell.com/about-us/leadership-team
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
